News

BIO-CAT Publishes Foundational Study of Digestive Enzyme Function

TROY, Va.,/PRNewswire/ — A clinical trial designed by BIO-CAT, Inc – a biotech company specializing in enzyme development – studied the use of enzymes to improve digestion in an in vitro model of aging. The results showed that a multi-component supplemental enzyme blend (microbial proteases, lipase, amylase, and glucoamylase) effectively released nutrients from a balanced meal better than control conditions, which solely relied upon endogenous enzymes similar to those already present in the human digestive system. Particularly impressive was the enhanced digestion during the acidic gastric phase, further confirming that the microbial enzymes are naturally acid-tolerant without encapsulation. The peer-reviewed manuscript describing these results is now published in the food science journal, Food Chemistry.

The BIO-CAT R&D team chose the INFOGEST model to adapt for the study of supplemental digestive enzymes. First described in 2014updated in 2019, and cited over 1500 times since, the INFOGEST simulation of human gastrointestinal digestion was developed by the International Network on Food Digestion with over 200 scientists from 32 countries. The INFOGEST protocol models each of salivary, gastric, and intestinal digestion with specific simulated digestion fluids, pH conditions, and enzymes to reflect human digestive physiology.

In a final series of experiments, the BIO-CAT team modified the INFOGEST protocol to model the decline in digestive function that accompanies each of advancing age and antacid use. Under both models of handicapped gastric conditions, the multi-enzyme blend was able to restore and improve macronutrient digestion and nutrient release. Additionally, BIO-CAT is now able to offer tailored INFOGEST testing for customers and partners.

The BIO-CAT publication comes on the heels of another exciting announcement from BIO-CAT. In January, the company initiated a clinical trial of the same multi-enzyme blend specifically in older adults aged 50-70 who may naturally experience changes in digestion. Study outcomes include changes nutrient absorption, gastrointestinal symptoms, and bowel function between the enzyme blend and placebo.

Read more here.

Recent News

05/14/2026

Owens & Minor Names Chief Operating Officer

Owens & Minor, a global healthcare solutions company providing essential products, services and technology solutions that support care delivery in leading hospitals, health systems and research centers around the world, today announced Marc Rottink as Chief Operating Officer (COO) of Owens & Minor, effective immediately. Rottink brings almost three decades of experience in leading global,

05/13/2026

BRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial Officer

BRAINBox Solutions today announced the appointment of Richard H. Noel to the newly created position of Chief Product and Commercial Officer. Richard brings more than 10 years of experience in molecular and point-of-care diagnostics, at Roche Diagnostics, LumiraDx, and bioMérieux. “Richard, whose expertise spans market analytics, global product management, and senior commercial leadership, has established

05/12/2026

Phlow Corp. Appoints Tim Mayleben Chief Executive Officer as Co-Founder Dr. Eric Edwards Transitions to Chairman Emeritus and Strategic Advisor

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Tim Mayleben has been appointed Chief Executive Officer, effective immediately. Eric Edwards, M.D., Ph.D., Phlow’s co-founder and former CEO, has transitioned to the role of Chairman Emeritus and Strategic Advisor to the CEO and Board of Directors. The leadership